The 12-month outcome of three consecutive monthly intravitreal injections of ranibizumab for myopic choroidal neovascularization

Journal of Ocular Pharmacology and Therapeutics

Volumn 28, Issue 2, 2012, Pages 129-133

  Wu, Tsung Tien ^a,b   Kung, Ya Hsin ^a,b,c  

^a KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB;

ADULT; AGED; ARTICLE; DRUG EFFICACY; DRUG SAFETY; EYE TOXICITY; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MYOPIA; OPTICAL COHERENCE TOMOGRAPHY; RECURRENT DISEASE; RETINA MACULA LUTEA; RETROSPECTIVE STUDY; SUBRETINAL NEOVASCULARIZATION; TREATMENT DURATION; TREATMENT OUTCOME; VISUAL ACUITY;

ADULT; AGED; ANGIOGRAPHY; ANTIBODIES, MONOCLONAL, HUMANIZED; CHOROIDAL NEOVASCULARIZATION; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; MALE; MEDICAL RECORDS; MIDDLE AGED; MYOPIA, DEGENERATIVE; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VISUAL ACUITY; YOUNG ADULT;

EID: 84859378676     PISSN: 10807683     EISSN: 15577732     Source Type: Journal    
DOI: 10.1089/jop.2011.0106     Document Type: Article

References (16)

1. Avila, M.P., Weiter, J.J., Jalkh, A.E., Trempe, C.L., Preutt, R.C., and Schepens, C.L. Natural history of choroidal neo-vascularization in degenerative myopia. Ophthalmology 91: 1573-1581, 1984. (Pubitemid 15197032)
2. Verteporfin in Photodynamic Therapy Study Group. Pho-todynamic therapy of subfoveal choroidal neovasculariza-tion in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial-VIP report no. 1. Ophthalmology 108:841-852, 2001.
3. Blinder, K.J., Blumenkranz, M.S., Bressler, N.M., Donato, G., Lewis, H., Lim, J.I., Menchini, U., Miller, J.W., Mones, J.M., Potter, M.J., Pournaras, C., Reaves, A., Rosenfeld, P., Scha-chat, A.P., Schmidt-Erfurth, U., Sickenberg, M., Singerman, L.J., Slakter, J.S., Strong, H.A., Virgili, G., and Williams, G.A. Verteporfin therapy of subfoveal choroidal neovasculariza-tion in pathologic myopia: 2-year results of a randomized clinical trial-VIP report no. 3. Ophthalmology 110:667-673, 2003. (Pubitemid 36520061)
4. Ciulla,T.A., Rosenfeld, P.J., Ciulla, T.A., and Rosenfeld, P.J. Antivascular endothelial growth factor therapy for neovas-cular age-related macular degeneration. Curr. Opin. Oph-thalmol. 20:158-165, 2009.
5. Ciulla, T.A., Rosenfeld, P.J., Ciulla, T.A., and Rosenfeld, P.J. Anti-vascular endothelial growth factor therapy for neo-vascular ocular diseases other than age-related macular degeneration. Curr. Opin. Ophthalmol. 20:166-174, 2009.
6. Heier, J.S., Brown, D., Ciulla, T., Abraham, P., Bankert, J.M., Chong, S., Daniel, P.E., Jr., and Kim, I.K. Ranibizumab for choroidal neovascularization secondary to causes other than age-related macular degeneration: A phase I clinical trial. Ophthalmology 118:111-118, 2011.
7. Cohen, S.Y., and Cohen, S.Y. Anti-VEGF drugs as the 2009 first-line therapy for choroidal neovascularization in pathologic myopia. Retina 29:1062-1066, 2009.
8. Silva, R.M., Ruiz-Moreno, J.M., Nascimento, J., Carneiro, A., Rosa, P., Barbosa, A., Carvalheira, F., Abreu, J.R.F., and Cunha-Vaz, J.G. Short-term efficacy and safety of in-travitreal ranibizumab for myopic choroidal neovascular-ization. Retina 28:1117-1123, 2008.
9. Konstantinidis, L., Mantel, I., Pournaras, J.A., Zografos, L., and Ambresin, A. Intravitreal ranibizumab (Lucentis) for the treatment of myopic choroidal neovascularization. Graefes Arch. Clin. Exp. Ophthalmol. 247:311-318, 2009.
10. Lai, T.Y.Y., Chan, W.M., Liu, D.T.L., and Lam, D.S.C. In-travitreal ranibizumab for the primary treatment of choroi-dal neovascularization secondary to pathologic myopia. Retina 29:750-756, 2009.
11. Mones, J.M., Amselem, L., Serrano, A., Garcia, M., and Hi-jano, M. Intravitreal ranibizumab for choroidal neovascu-larization secondary to pathologic myopia: 12-month results. Eye 23:1275-1280, quiz 1281, 2009.
12. Lalloum, F., Souied, E.H., Bastuji-Garin, S., Puche, N., Querques, G., Glacet-Bernard, A., Coscas, G., Soubrane, G., and Leveziel, N. Intravitreal ranibizumab for choroidal neovascularization complicating pathologic myopia. Retina 30:399-406, 2010.
13. Silva, R.M., Ruiz-Moreno, J.M., Rosa, P., Carneiro, A., Nas-cimento, J., Rito, L., Cachulo, M.L., Carvalheira, F., and Murta, J.N. Intravitreal ranibizumab for myopic choroidal neovascularization: 12-month results. Retina 30:407-412, 2010.
14. Calvo-Gonzalez, C., Reche-Frutos, J., Donate, J,. Fernandez-Perez, C., and Garcia-Feijoo, J. Intravitreal ranibizumab for myopic choroidal neovascularization: factors predictive of visual outcome and need for retreatment. Am. J. Ophthalmol. 151:529-534, 2011.
15. Lalwani, G.A., Rosenfeld, P.J., Fung, A.E., Dubovy S.R., Mi-chels, S., Feuer, W., Davis, J.L., Flynn, H.W., Jr., and Esquiabro, M. A variable-dosing regimen with intravitreal ranibizumab for neovascular agerelated macular degeneration: Year2 of the PrONTO Study. Am. J. Ophthalmol. 148:43-58, 2009.
16. Tong, J.P., Chan, W.M., Liu, D.T., Lai, T.Y.Y., Choy, K-W., Pang, C-P., and Lam, D.S.C. Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization. Am. J. Ophthalmol. 141:456-462, 2006. (Pubitemid 43265948)